Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele, Merck to Search for SNPs Linked to Cancer Risk, Drug Response

NEW YORK, July 7 (GenomeWeb News) - ParAllele BioScience and Merck plan to co-discover SNPs linked to cancer susceptibility, prognosis, or drug response, the companies said today.

The deal, which is being funded by Merck, ParAllele will use its SNP-genotyping technology to "characterize the genetic changes in tumor samples" identified by the US-based drug maker.

 

Details of the agreement were not disclosed.

 

This is at least the second such collaboration for the companies. Almost exactly two years ago, ParAllele said it would use its lab-in-a-tube technology to develop assays, perform multiplexed genotyping, and provide data analysis for Merck.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.